SpliSense

RNA-based Treatment for Genetic Diseases

Startup

SpliSense is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2016. RNA-based Treatment for Genetic Diseases. The company has raised a total of $41.5M across 4 funding rounds, currently at the B stage. Key investors include Cystic Fibrosis Foundation, Integra Holdings, OrbiMed, among 5 total investors. The company has 11-50 employees. Core technologies: Biologicals, Genes.

With $41.5M in total funding, SpliSense is a B-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.

$41.5M
Raised
4
Rounds
6
Investors
3
Team
2016
Founded
1
Patents
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiologicalsGenes
At a Glance
Investors

5 investors total

In the News

6 articles covered by sources including www.prnewswire.com, www.jpost.com, www.israel21c.org, cysticfibrosisnewstoday.com.

www.prnewswire.com · Sep 3, 2025
/PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced...
Read article ↗
Frequently Asked Questions
What does SpliSense do?

SpliSense is a clinical stage company developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. Its treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs. The company is focused on a variety of innovative therapies, in different development stages from discovery to IND. Using an innovative approach, SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and modulate proteins expression and function. The company recieved FDA approval for its lead ASO product, SPL84, for the treatment of patients with cystic fibrosis.

How much funding has SpliSense raised?

SpliSense has raised $41.5M in total funding across 4 rounds. The company is currently at the B stage. Key investors include Cystic Fibrosis Foundation, Integra Holdings, OrbiMed.

What sector is SpliSense in?

SpliSense operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.

Where is SpliSense located?

SpliSense is based in Kalman Ya'akov Man St, Jerusalem, Israel, Jerusalem District.

View Full Profile Classic View Website ↗